PostEra

PostEra launched with a deliberately narrow MVP: a machine learning platform that predicted molecular structures for specific drug targets, paired with a small team of medicinal chemists who validated predictions experimentally. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Rather than building a comprehensive drug discovery suite, they shipped within months by focusing exclusively on the molecular design layer—deliberately excluding manufacturing optimization, regulatory pathway planning, and clinical trial infrastructure. This constraint forced speed and clarity. Early validation came quickly through partnership discussions with pharma companies desperate for faster hit-to-lead timelines; Amgen and Pfizer's willingness to commit multi-year agreements signaled the market urgently needed their specific capability. The execution approach—pairing AI predictions with human chemistry expertise rather than pursuing fully autonomous discovery—proved crucial. It prevented the common trap of over-engineering before market fit while building credibility with conservative pharma partners who needed human accountability. This hybrid model became their competitive moat, attracting the $26M in funding and $1B in partnership value that followed.